logo

MDGL

MadrigalยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

MDGL Profile

Madrigal Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis

Biological Technology
--
02/06/2007
NASDAQ Stock Exchange
528
12-31
Common stock
Four Tower Bridge, 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania
--
Madrigal Pharmaceuticals, Inc., was established in March 2000 and began operations in July 2001. Synta Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecule drugs to expand and enhance the lives of patients with serious diseases, including cancer and chronic diseases. The company has two drug candidates in clinical trials for the treatment of various types of cancer and several drug candidates in the preclinical research phase. All of the company's drug candidates are discovered using the company's patents, unique compounds and integrated discovery engines. The company retains all options on its drug candidates.